109170 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar 2'-O-R Modification
LNA-G process
#1502Thiomorpholino oligonucleotides for the treatment of muscular dystrophy
#1503RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
#1504Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof
#1505Oligonucleotide compositions and methods thereof
#1506RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
#1507MODIFIED CPF1 GUIDE RNA
#1508Compositions and methods for inhibiting HMGB1 expression
#1509TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#1510HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1511Methods for the treatment of Leber congenital amaurosis
#1512Oligonucleotide comprising an inosine for treating DMD
#1513Exosomal loading using hydrophobically modified oligonucleotides
#1514RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
#1515Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#1516Methods and compositions for inhibiting expression of LDHA
#1517Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#1518Compositions and Methods for Inhibiting Expression of Transthyretin
#1519Methods for Treatment of Alport Syndrome
#1520Method for producing complex of RNA molecule and peptide, and utilization thereof
#1521Compositions and methods for inhibiting expression of RRM2 genes
#1522RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1523Modulators of MALAT1 expression
#1524Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof
#1525Methods and compositions for modulating splicing
#1526METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#1527ANTISENSE COMPOUNDS
#1528Single-Stranded RNAI Oligonucleotides Targeting APOC-III
#1529Modulation of huntingtin expression
#1530Beta catenin nucleic acid inhibitor molecule
#1531Dynamic pharmacokinetic-modifying anchors
#1532GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF
#1533Complement component iRNA compositions and methods of use thereof
#1534Oligomers
#1535COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA
#1536Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes
#1537Compositions and methods for treating transposon associated diseases
#1538Therapeutic compositions
#1539Antisense oligonucleotides for the treatment of leber congenital amaurosis
#1540Stabilized HNF4A saRNA compositions and methods of use
#1541HNF4A saRNA compositions and methods of use
#1542POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
#1543Agents that modulate TMEM230 as angiogenesis regulators and that detect TMEM230 as markers of metastasis
#1544Methods and compositions for modulating splicing
#1545Compositions and methods for inhibition of expression of protein C (PROC) genes
#1546Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene
#1547Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
#1548Compositions for modulating expression of C9ORF72 antisense transcript
#1549Exponential base-3 and greater nucleic acid amplification with reduced amplification time
#1550Oligonucleotides to treat eye disease
#1551Reducing intron retention
#1552Double-stranded RNA molecule targeting CKIP-1 and use thereof
#1553Agents useful in treating facioscapulohumeral muscular dystrophy
#1554Nucleic acid oligomers and uses therefor
#1555ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES, THE HCHWA-D MUTATION, AND TRINUCLEOTIDE REPEAT EXPANSIONS
#1556Methods and compositions for modulating splicing
#1557COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#1558Stem-loop compositions and methods for inhibiting factor D
#1559SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1560GENE EDITING T CELL AND USE THEREOF
#1561CHEMICALLY MODIFIED OLIGONUCLEOTIDES
#1562Products and compositions
#1563ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
#1564STABILIZED SARNA COMPOSITIONS AND METHODS OF USE
#1565Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#1566Modulators of IRF5 expression
#1567Modified messenger RNA comprising functional RNA elements
#1568GENOME-EDITED NK CELL AND METHODS OF MAKING AND USING
#1569LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1570Allele-specific therapy for Huntington disease haplotypes
#1571siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
#1572Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
#1573Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#1574Targeted RNA editing
#1575COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#1576MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#1577Organic compositions to treat EPAS1-related diseases
#1578MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF
#1579Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#1580Antisense oligonucleotides for the treatment of eye disease
#1581COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#1582COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
#1583Modified Cpf1 MRNA, modified guide RNA, and uses thereof
#1584Ketohexokinase (KHK) iRNA compositions and methods of use thereof
#1585Methods for treating hepatitis B infection
#1586Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#1587RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1588Compositions and methods for the treatment of complications and disorders relating to Von Willebrand Factor
#1589Therapeutic splice-switching oligonucleotides
#1590Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
#1591RNAi inhibition of alpha-ENaC expression
#1592COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#1593Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)
#1594METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#1595MODULATORS OF COMPLEMENT FACTOR B
#1596RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
#1597Antisense nucleic acids
#1598Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
#1599Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1600Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
#1601COMPOUNDS THAT TARGET MYC microRNA RESPONSIVE ELEMENTS FOR THE TREATMENT OF MYC-ASSOCIATED CANCER
#1602Methods and means for treating DNA repeat instability associated genetic disorders
#1603Myostatin iRNA compositions and methods of use thereof
#1604Molecules and agents for treating hepatitis B virus
#1605Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
#1606Antisense compounds targeting genes associated with cystic fibrosis
#1607Compositions and methods for modulating growth hormone receptor expression
#1608TREATMENT OF ANGIOGENESIS-ASSOCIATED DISEASES USING RNA COMPLEXES THAT TARGET ANGPT2 AND PDGFB
#1609NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#1610Modulation of angiopoietin-like 3 expression
#1611HETERO DOUBLE-STRANDED antimiR
#1612Antisense nucleic acids
#1613LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1614Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
#1615Methods of reducing expression of x-inactivation escapee genes and autosomal genes
#1616Antisense nucleic acids
#1617Antisense nucleic acids
#1618Therapeutic uses and methods
#1619Methods and compositions for managing vascular conditions
#1620MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS
#1621Products and compositions
#1622O-methyl rich fully stabilized oligonucleotides
#1623Inhibition of poly(A) binding protein and the treatment of pain
#1624Compositions for modulating Ataxin 2 expression
#1625APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1626Twist signaling inhibitor compositions and methods of using the same
#1627Serpina1 iRNA compositions and methods of use thereof
#1628OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1629Therapeutic drug for Alport's syndrome
#1630Compositions of asymmetric interfering RNA and uses thereof
#1631COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1632MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
#1633Products and compositions
#1634Compositions of asymmetric interfering RNA and uses thereof
#1635Oligonucleotides for inducing paternal UBE3A expression
#1636Post-selex modification methods
#1637MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#1638COMPOSITIONS AND METHODS FOR INHIBITIION OF EXPRESSION OF PROTEIN C (PROC) GENES
#1639Oligonucleotide compositions and methods thereof
#1640Modified nucleic acids, hybrid guide RNAs, and uses thereof
#1641COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
#1642RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1643Compositions and methods for the treatment of hypercholesterolemia
#1644Compositions for modulating SOD-1 expression
#1645Compositions and methods for modulating SMN gene family expression
#1646Oligonucleotide Probes and Uses Thereof
#1647Compositions and methods for modulation of IKBKAP splicing
#1648Complement component C5 iRNA compositions and methods of use thereof
#1649COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1650Methods for treating Alzheimer's disease
#1651Antisense oligomers for treatment of conditions and diseases
#1652Antisense oligomers for treatment of conditions and diseases
#1653Antisense oligonucleotides to treat dystrophic epidermolysis bullosa
#1654Oligomers
#1655Targeting human satellite II (HSATII)
#1656Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
#1657MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#1658Oligonucleotides for modulating Tau expression
#1659Reduced size self-delivering RNAI compounds
#1660Modulation of Factor 11 expression
#1661Interfering RNA molecules
#1662Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#1663Methods and systems for guide RNA design and use
#1664Antisense oligonucleotides for use in treating Alzheimer's disease
#1665MODIFIED CRISPR RNA AND USES THEREOF
#1666Oligonucleotides to treat eye disease
#1667Anti-IL-17 aptamer having improved retention in blood
#1668METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS
#1669siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof
#1670Methods and compositions for treating malignant tumors associated with KRAS mutation
#1671Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor
#1672Antisense oligonucleotides that inhibit influenza virus replication and uses thereof
#1673Antisense oligonucleotides for the treatment of Stargardt disease
#1674Compositions for modulating C9ORF72 expression
#1675Conjugated antisense compounds and their use
#1676Modulators of APOL1 expression
#1677Serpina1 siRNAs: compositions of matter and methods of treatment
#1678Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1679Modified iRNA agents
#1680Bi-specific aptamer
#1681Modulation of Lnc05 expression
#1682Artificial exosome composition and related methods
#1683RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1684SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#1685RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
#1686Method for generating aptamers with improved off-rates
#1687COMPOUNDS AND METHODS FOR USE IN DYSTROPHIN TRANSCRIPT
#1688Single-stranded RNA-editing oligonucleotides
#1689SiRNA structures for high activity and reduced off target
#1690ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#1691TNF-alpha-binding aptamer, and therapeutic use for same
#1692Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#1693ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
#1694COMPOUNDS AND METHODS FOR MODULATION OF SMN2
#1695Pharmaceutical compositions and methods for potentiating gene silencing
#1696COMPOUNDS AND METHODS FOR MODULATION OF TRANSCRIPT PROCESSING
#1697Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1698Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides
#1699ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS
#1700Antisense nucleic acids
#1701Oligonucleotides for inducing paternal UBE3A expression
#1702RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
#1703Antisense oligonucleotides
#1704Compositions and Methods for Inhibiting Expression of Transthyretin
#1705Methods for enhancing utrophin production via inhibition of microRNA
#1706METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
#1707RNAi agents for Hepatitis B virus infection
#1708METHOD FOR EFFICIENT EXON (44) SKIPPING IN DUCHENNE MUSCULAR DYSTROPHY AND ASSOCIATED MEANS
#1709Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin
#1710DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES
#1711MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#1712Organic compositions to treat HSF1-related diseases
#1713Antisense molecules and methods for treating pathologies
#1714Compositions for delivery of cargo to cells
#1715Antisense compounds and uses thereof
#1716Polymerizable compound, compound, and method for producing boranophosphate oligomer
#1717COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS
#1718Modulation of gene expression and screening for deregulated protein expression
#1719Method for Generating Aptamers with Improved Off-Rates
#1720Therapeutic compositions
#1721GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS
#1722TGF-beta oligonucleotide for use in treatment of ophthalmic diseases
#1723CCR7 aptamers and uses thereof
#1724RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1725Targeting ligands
#1726Antisense oligonucleotides for the treatment of eye disease
#1727COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
#1728Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
#1729Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
#1730Modulation of huntingtin expression
#1731Compounds and methods for reducing ATXN3 expression
#1732Antisense oligonucleotides useful in treatment of Pompe disease
#1733MOLECULAR RE-ENGINEERING OF EXCITATION-INHIBITION BALANCE IN MEMORY CIRCUITS
#1734Lipid formulations for delivery of therapeutic agents
#1735Modulation of prekallikrein (PKK) expression
#1736RNA interference in ocular indications
#1737Organic compositions to treat APOC3-related diseases
#1738Compositions and methods for the treatment of expanded repeat-associated disorders
#1739MODULATORS OF GROWTH HORMONE RECEPTOR
#1740MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#1741INHIBITION OF PCSK9 THROUGH RNAI
#1742Mixed tricyclo-DNA, 2′-modified RNA oligonucleotide compositions and uses thereof
#1743COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#1744Antisense nucleic acids
#1745Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
#1746TMPRSS6 iRNA compositions and methods of use thereof
#1747Anti-TNF compounds
#1748Neutral nanotransporters
#1749Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#1750Compositions, methods and systems for identifying candidate nucleic acid agent
#1751Targeting Ligands For Therapeutic Compounds
#1752Antisense nucleic acids
#1753Antisense nucleic acids
#1754Modulation of GYS1 expression
#1755ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#1756RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
#1757Aptamer therapeutics useful in the treatment of complement-related disorders
#1758Peptide nucleic acid complex having improved cell permeability and pharmaceutical composition comprising same
#1759Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
#1760Nucleic acids and methods for the treatment of Pompe disease
#1761MODULATION OF TRANSTHYRETIN EXPRESSION
#1762Modified RNAi polynucleotides and uses thereof
#1763Reduced size self-delivering RNAI compounds
#1764Targeted nucleic acid conjugate compositions
#1765Targeting MicroRNAs for Metabolic Disorders
#1766Compositions and methods for inhibiting expression of the ALAS1 gene
#1767Allele-specific gene suppression
#1768RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1769MODIFIED TGF-BETA OLIGONUCLEOTIDE FOR USE IN A METHOD OF PREVENTING AND/OR TREATING AN OPHTHALMIC DISEASE
#1770MicroRNA Compounds and Methods for Modulating MIR-122
#1771Modulating the cellular stress response
#1772Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#1773Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
#1774Compositions and methods for modulating neuronal excitability and motor behavior
#1775STANDARDIZED NEURONAL CELL ASSAYS FROM PRIMATE SPECIES
#1776TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS AND OLIGONUCLEOTIDE FORMULATIONS
#1777GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
#1778MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#1779SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III
#1780Compositions and methods for inhibiting expression of TMPRSS6 gene
#1781METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
#1782COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
#1783METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
#1784Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#1785Oligomers
#1786siRNA And Their Use In Methods And Compositions For Inhibiting The Expression Of The ORAI1 Gene
#1787GNAQ targeted dsRNA compositions and methods for inhibiting expression
#1788Methods and compositions for treating atherosclerosis
#1789Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53
#1790Compositions and methods for treating diabetic retinopathy
#1791Defined multi-conjugate oligonucleotides
#1792Amine cationic lipids and uses thereof
#1793Antisense oligonucleotides for the treatment of Leber congenital amaurosis
#1794DOWNREGULATING MIR-132 FOR THE TREATMENT OF LIPID RELATED DISORDERS
#1795RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
#1796Polynucleotides containing a morpholino linker
#1797Modulation of DYRK1B expression
#1798Methods for treating hypercholesterolemia
#1799RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1800Pharmaceutical Composition